Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.55 |
| ▸ | JAK1 | P23458 | 3/20 | 0.55 |
| ▸ | ULK1 | O75385 | 2/20 | 0.49 |
| ▸ | ITK | Q08881 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
| ▸ | HTR1F | P30939 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5309301 | 0.92 | JAK2 (0.53) | JAK2JAK1ULK1ITKKMT2A | |
| SCHEMBL5308089 | 0.85 | HTR1A (0.50) | ULK1ITKNPC1RAB9AHTR1D | |
| SCHEMBL5311430 | 0.85 | JAK2 (0.46) | JAK2JAK1ITKKMT2ALRRK2 | |
| SCHEMBL5302823 | 0.83 | JAK2 (0.43) | JAK2JAK1ULK1ITKKMT2A | |
| SCHEMBL5906211 | 0.83 | ABL1 (0.56) | ITKKMT2ANPC1RAB9AHTR1D | |
| SCHEMBL8148201 | 0.82 | ULK1 (0.44) | JAK2JAK1ULK1ITKBRD4 | |
| SCHEMBL8148939 | 0.81 | ULK1 (0.44) | JAK2JAK1ULK1ITKBRD4 | |
| SCHEMBL5314358 | 0.81 | ABL1 (0.56) | ITKKMT2ANPC1RAB9AHTR1D | |
| SCHEMBL5309428 | 0.80 | LRRK2 (0.42) | JAK2JAK1RAB9AHTR1DHTR1A | |
| SCHEMBL5311761 | 0.80 | MEN1 (0.43) | JAK2JAK1ULK1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841427-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | Pozen, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | POZEN INC. (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2006081127-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | POZEN INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-0978514-B1 | Indazole derivatives as 5-HT1F agonists | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6133290-A | 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000006173-A1 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0978514-A1 | Indazole derivatives as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2000-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | HTR1F, HTR1A, HTR1E | JAK2 1471/4885JAK1 1743/4885ULK1 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.